Veeva Systems Inc. — Form 10-K Summary
Business and period: Veeva provides cloud software, data, and services, primarily to life sciences companies. This annual report covers the fiscal year ended January 31, 2021; it also reports the quarter ended that date. Figures are in U.S. dollars.
Financial performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $1.465 billion | $1.104 billion |
| Subscription services revenue | $1.179 billion; +32% | $896 million; +29% |
| Professional services and other revenue | $286 million; +37% | $208 million |
| Gross profit / gross margin | $1.056 billion / 72% | $801 million / 73% |
| Operating income / margin | $378 million / 25.8% | $286 million / 25.9% |
| Net income / diluted EPS | $380 million / $2.36 | $301 million / $1.90 |
| Operating cash flow | $551 million | $437 million |
Q4 FY2021: Revenue was $396.8 million, gross profit $282.9 million, operating income $98.8 million, and net income $102.9 million; diluted EPS was $0.64.
Liquidity and capital: Cash and cash equivalents were $731 million and short-term investments $933 million at year-end, totaling $1.664 billion. Working capital was $1.595 billion. Total liabilities were $780 million, including $617 million of deferred revenue and $63 million of operating lease liabilities. The filing reports no borrowings; it does not identify conventional debt as a material funding source. FY2021 investing cash outflow was $334 million and financing cash inflow was $34 million.
Changes and business drivers
- Revenue grew 33%, versus 28% in FY2020. Subscription revenue growth accelerated to 32% from 29%; management expects growth rates to decline over time.
- Vault subscription revenue increased $152 million and Commercial Cloud increased $131 million. Vault’s share of revenue is expected to rise.
- Gross margin slipped one percentage point, partly because acquired Crossix and Physicians World businesses carried lower margins. Operating expenses grew 32%, led by research and development, which rose 40%.
- Customer count increased to 993 from 861. Subscription revenue retention was 124%, compared with 121% in FY2020.
- Cash from operations increased $114 million. Investing outflow declined from the prior year, which included $448 million of acquisition spending.
Outlook, risks, and unusual items
- The filing does not provide a specific numeric revenue or earnings forecast. Management expects operating expenses and investment in products, sales capacity, infrastructure, and personnel to increase; this may pressure operating margins.
- COVID-19 had not materially harmed overall performance to date, but its future effects were uncertain. Crossix and Physicians World were negatively affected. Virtual engagement products saw accelerated adoption, including high conversion to paid subscriptions after a free-use period for Engage Meeting.
- Management anticipates life sciences companies may reduce sales-representative headcount by roughly 10% over the next one to two years, potentially weighing on CRM demand; timing and scale are uncertain.
- Material risks include competition, especially from IQVIA; limits on use of third-party data; reliance on Salesforce for CRM infrastructure and an agreement expiring in 2025; cybersecurity, privacy, regulatory, and service-continuity risks; customer concentration; and international exposure. The top 10 customers contributed 36% of revenue.
- Veeva became a Delaware public benefit corporation on February 1, 2021, after the reporting year. Its board must balance stockholder financial interests with stakeholder interests and its stated public-benefit purpose. Dual-class voting control remains concentrated until October 15, 2023, absent earlier conversion.
- IQVIA and Medidata litigation remained ongoing. The filing says outcomes and potential losses could not be reliably estimated; Veeva also asserts claims against IQVIA. Legal costs are expected to continue. The Salesforce agreement carried $57 million of remaining minimum purchase commitments through September 2025.
- Stock-based compensation was $185 million, up from $116 million. Non-GAAP results exclude stock-based compensation and acquired-intangible amortization; GAAP results remain the primary reported figures.
Important facts for investors to verify
- Whether Vault growth continues to offset mature CRM penetration and potential reductions in sales-representative numbers.
- Renewal, expansion, and pricing trends, along with the sustainability of the 124% subscription revenue retention rate.
- Margin trajectory as hiring, data acquisition, infrastructure, and litigation costs rise; assess the effect of stock-based compensation on reported results.
- Customer access to third-party data and the development of the competitive CRM deployment at a significant customer.
- Developments and possible costs in the IQVIA and Medidata disputes, and the Salesforce relationship ahead of its 2025 expiry.
- Effects of COVID-19, privacy and regulatory changes, and the PBC governance structure on demand, costs, and stockholder interests.